Press releases
- Incyte to Present at Upcoming Investor Conference
- Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
- Incyte to Present at Upcoming Investor Conferences
- Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
- Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
- Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
- Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
- Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
- More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
- Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
More ▼
Key statistics
On Friday, Incyte Corp (ICY:BER) closed at 78.86, -4.05% below its 52-week high of 82.19, set on Jul 21, 2022.
52-week range
Markit short selling activity
Open | 79.03 |
---|---|
High | 79.11 |
Low | 78.79 |
Bid | -- |
Offer | -- |
Previous close | 78.99 |
Average volume | 30.00 |
---|---|
Shares outstanding | 222.48m |
Free float | 218.93m |
P/E (TTM) | 21.78 |
Market cap | 19.07bn USD |
EPS (TTM) | 3.94 USD |
Data delayed at least 15 minutes, as of Jan 27 2023 20:52 GMT.
More ▼